December 2007 PMID 18063357

Replicating and non-replicating viral vectors for vaccine development.

Marjorie Robert-Guroff

Full text PDF Download social card

Mentions

Peak: 1 in Sep 2020

across 4 sources since Sep 2020

Extended reach

304,125

potential audience

Total likes

3,034

Video views

301,602

Mentions per month

Sep 2020 – Apr 2024

Where it's discussed

News10 articles
YouTube3 videos
Blogs3 articles
X / Twitter2 posts

AI synopsis

What people are saying

The discussions reflect a balanced appreciation of the article, with mentions of how viral vectors deliver antigens and their role in vaccine strategies, indicating a moderate but meaningful engagement. The tone is technical but accessible, with phrases like 'convenient means' and 'strategy' highlighting interest and perceived importance.

AgreementModerate agreement

Most discussions acknowledge the value of viral vectors in vaccine development, reflecting general support.

InterestModerate interest

Participants show moderate curiosity about the topic, indicating a reasonable level of engagement but not deep passion.

EngagementModerate engagement

Comments include references to specific applications, such as HIV vaccine strategies, suggesting some detailed understanding.

ImpactModerate impact

The emphasis on research methods and potential uses suggests these discussions see the article as moderately influential in the field.

Abstract in brief

Viral vectors are used to deliver vaccine antigens directly to specific cells or tissues, offering a flexible approach for vaccine development.
The choice between replicating and nonreplicating vectors depends on factors like the infectious agent's biology, the goal of the vaccine (preventing infection or boosting immunity), and safety concerns.
A common HIV vaccine strategy involves priming with a replicating vector to activate immune responses, followed by boosting with either a similar or nonreplicating vector, or protein subunits, to achieve strong protective immunity.]

Read the full abstract